hrp0092rfc14.5 | Adrenals and HP Axis | ESPE2019

Bioactive IGF-I Concentration Compared to Total IGF-I Concentration Before and After 1 Year of High-Dose Growth Hormone in Short Children Born Small for Gestational Age - North European SGA Study (NESGAS)

Beck Jensen Rikke , Gersel Wegmann Mathilde , Thankamony Ajay , Roche Edna , Hoey Hilary , Kirk Jeremy , Ivarsson Sten-A. , Söder Olle , Frystyk Jan , Dunger David B. , Juul Anders

Background: Children born small for gestational age (SGA) exhibit wide variations in the activity of growth hormone (GH)/insulin–like growth factor–I (IGF-I) axis and this heterogeneity may result in supra physiological concentrations of IGF-I during GH treatment. The long-term effects of elevated IGF-I levels has been a matter of concern. We explored the variations in total IGF-I and bioactive IGF-I and the associations with growth and glucose metab...

hrp0092p1-213 | GH and IGFs (1) | ESPE2019

Determinants of Final Height in Patients Born Small for Gestational Age Treated with Recombinant Growth Hormone

Adler Elodie , Lambert Anne-sophie , Bouvattier Claire , Teinturier Cécile , Bougnères Pierre , Rodrigue Danielle , Rothbuhler Anya , De Boissieu Paul , Linglart Agnès

Introduction: About 15% of children born small for gestational age (SGA) do not reach final height within normal range. Recombinant human growth Hormone (rhGH) has shown to be effective in catching up growth velocity and height in children born SGA.The objective of our study is to identify the predictive factors of final height in children born SGA treated with rhGH.Materials and Methods: Monocentric, retrospective s...

hrp0092p2-171 | GH and IGFs | ESPE2019

Final Height in GH-deficient Paediatric Patients: A Nationwide Experience

Zucchini Stefano , Lonero Antonella , Bellone Simonetta , Bozzola Mauro , Cassio Alessandra , Felicia Faienza Maria , Giacomozzi Claudio , Grandone Anna , Guzzetti Chiara , Iughetti Lorenzo , Parpagnoli Maria , Salerno Mariacarolina , Elizabeth Street Maria , Tornese Gianluca , Wasniewska Malgorzata , Delvecchio Maurizio

Background: The primary goal of GH treatment in GHD children and adolescents is to normalize height, in order to attain an adult height within the target height (TH) range.Aim: to investigate height improvement in GHD paediatric patients treated with GH in our Country.Subjects: 737 patients with isolated GHD (39.5% females) from 13 tertiary Centres for Paediatric Endocrine Care...

hrp0092p1-82 | GH and IGFs | ESPE2019

Positive Impact on Adherence Through Educational Activities of the Argentina´s Patient Support Program in Children with low Adherence to Treatment with Recombinant Growth Hormone (easypod applicator)

Assefi Aria Reza , Chareca Cinthia , Roca Fernanda , Rubstein Adrian , Ayala Luciana Celis , Von Schulz Hausmann Cristian

Background: One of the main concerns in patients with growth disorders is to achieve optimal adherence to growth hormone (GH) treatment. For this it is important to identify patients with low adherence to treatment and to evaluate actions to improve it.The Merck Patient Support Program (PSP) carried out educational actions aimed at patients with low adherence and their parents, to raise their awareness of the importance of good adherence...

hrp0092p1-130 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2019

In vivo and In vitro study of 17β Estradiol Against Amyloid Beta Neurotoxicity in Synaptosomes of Aging Female Rats: A Therapeutic Potential Drug for Parkinson's Disease

Kumar Pardeep , Baquer Najma

Objectives: The aim of the present study was to determine the effects of neuropeptide, neurokinin B (NKB) and amyloid beta fragment Aβ (25-35) on 17β estradiol (E2) treated aging female rat brain of 3 months (young), 12 months (adult) and 24 months (old) age groups.Methods: The aged rats (12 and 24 months old) were given subcutaneous injection of E2 (0.1 µg/g body weight) for 30 days. Synaptosomes we...

hrp0095p1-471 | Fat, Metabolism and Obesity | ESPE2022

Higher cognitive scores in 6-year-old children with healthier lifestyle: more physical activity and sleep time

Bassols Judit , Sanchez Mario , Carreras-Badosa Gemma , Gómez-Vilarrubla Ariadna , Mas-Parés Berta , Puerto-Carranza Elsa , de Zegher Francis , Ibañez Lourdes , Garre Josep , López-Bermejo Abel

Background and aims: Studies in adults and experimental animals suggest an inverse and bidirectional relationship between cognitive abilities and obesity. Clinical studies on cognition and obesity in children are scarce and methodologically heterogeneous. Indeed, various factors related to obesity including diet, physical activity, socioeconomic status and maternal obesity can affect neuropsychological development. We aimed to study the cognitive function in s...

hrp0095p1-303 | GH and IGFs | ESPE2022

Short stature due to a novel missense variant (695C>A) in the GHR gene: a case report.

Righi Beatrice , Trimarchi Gabriele , De Fanti Alessandro , Garavelli Livia , Sartori Chiara , Elisabeth Maria

Introduction: Laron Syndrome (LS) or primary growth hormone (GH) insensitivity is an autosomal recessive disorder due to variants in the GH-receptor (GHR) gene or to post-receptor defects. LS prevalence is estimated 1-9/1000000. We report a case of LS with a missense variant in the GHR gene not previously described.Case: female, Turkish, was referred to our clinic for short stature. Born at term, birth ...

hrp0095p1-533 | Growth and Syndromes | ESPE2022

Central Precocious Puberty in McCune Albright Syndrome: a case report.

Righi Beatrice , Peluso Francesca , De Fanti Alessandro , Garavelli Livia , Elisabeth Street Maria , Sartori Chiara

Introduction: McCune Albright Syndrome (MAS) is a rare disorder caused by somatic activating mutations of the GNAS gene, characterized by monostotic/polyostotic fibrous dysplasia, café au lait skin pigmentation and hyperfunctioning endocrinopathies. We report a case of MAS presenting with mild phenotypic characteristics and central precocious puberty (CPP).Case: Indian female was referred to our clinic fo...

hrp0092p1-382 | Growth and Syndromes (to include Turner Syndrome) (2) | ESPE2019

Nutritional Requirements in Prader Willi Syndrome Children Treated with Growth Hormone Under Two Years of Age

Corripio Raquel , Franch Noemi , Couto Yolanda , Pérez Jacobo , Gabau Elisabeth , Capdevila Nuria , Rivera Josefa

Background: Prader Willi Syndrome (PWS) patients under treatment with growth hormone (GH) have a better body composition and cognitive performance than untreated patients. The 2013 guideline recommended to start this treatment as soon as possible, for that reason 14 toddlers have been included in our center. Classically a 25% decrease in the caloric intake of PWS patients has been recommended to avoid obesity. However, from clinical practice observation, w...

hrp0089p1-p046 | Diabetes & Insulin P1 | ESPE2018

Phenotypes of Diabetes and Determinants of Glycemic Control and Diabetes Complications in Haitian Youth Living in Haiti

Dumas Marie-Pier , Sainvil Michele , Altenor Kelty , von Oettingen Julia Elisabeth

Background: In non-Caucasian youth residing in low-income settings, risk of mortality and rates of diabetes complications are substantially higher and clinical phenotypes may be distinct.Objectives: To assess the clinical presentation, glycemic control, and chronic complications of diabetes in Haitian youth residing in Haiti.Methods: Retrospective review between 01/2013–03/2018 of youth 0-25 years with diabetes followed at a c...